Arcturus Therapeutics Holdings Inc. ARCT

ARCT Company Overview

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on the development of RNA medicines and vaccines using messenger RNA (mRNA) technologies. The company operates primarily in the biotechnology and pharmaceutical industries, with a concentration on infectious diseases, rare diseases, and chronic conditions that may benefit from nucleic acid-based therapeutics. Arcturus is known for its proprietary lipid-mediated delivery and self-amplifying mRNA technology platforms, which are intended to improve the durability and efficiency of RNA expression. The company generates value primarily through research and development collaborations, licensing arrangements, government-supported vaccine programs, and advancement of proprietary therapeutic candidates.

The company’s core technology platforms include LUNAR® lipid nanoparticle delivery technology and self-amplifying mRNA platforms designed for lower-dose therapeutic and vaccine applications. Arcturus has pursued strategic positioning through partnerships with government agencies and pharmaceutical organizations, particularly in vaccine development and pandemic preparedness initiatives. Founded in 2013 and headquartered in San Diego, California, the company evolved from an early-stage RNA therapeutics developer into a broader clinical-stage biotechnology company with programs spanning respiratory vaccines and rare genetic diseases.